TCR2 Therapeutics Inc. (TCRR) Investment Research Dashboard
About TCR2 Therapeutics Inc. (TCRR) stock analysis
Get live TCRR stock price $1.48, comprehensive TCR2 Therapeutics Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time TCRR stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell...
Company Information
- CEO
- Garry E. Menzel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
Contact Information
- Website
- https://www.tcr2.com
- Address
- 100 Binney Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.93)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for TCR2 Therapeutics Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for TCR2 Therapeutics Inc.
- ⚠Investors should consider how TCR2 Therapeutics Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
58.11M
P/E Ratio (TTM)
-0.35
Beta
1.93
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare TCRR with peer companies:
- Price
- $1.48+0.00% (1D)
- Market cap
- 60.83M
- Price
- $4.97+0.00% (1D)
- Market cap
- 48.67M
- Price
- $0.30+0.00% (1D)
- Market cap
- 45.43M
- Price
- $2.38+0.00% (1D)
- Market cap
- 61.07M
- Price
- $0.88+0.00% (1D)
- Market cap
- 53.65M
- Price
- $1.42+0.00% (1D)
- Market cap
- 32.92M
- Price
- $18.20+0.00% (1D)
- Market cap
- 60.84M
- Price
- $22.47+0.00% (1D)
- Market cap
- 56.22M
- Price
- $1.07+0.00% (1D)
- Market cap
- 65.08M
- Price
- $99.96-0.08% (1D)
- Market cap
- 8.68B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
80/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +5.7% | +6.1% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | +2.9% | +4.3% | 22.2 | 86/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +3.3% | +3.5% | 24.1 | 80/100⭐⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.1% | -0.2% | 25.2 | 56/100⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.7% | +1.2% | 29.7 | 56/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | -0.1% | -1.6% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -5.8% | -5.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | -3.0% | -5.9% | 26.8 | 28/100⭐⭐ |
| Industrials | +0.6% | +1.7% | -11.2% | 30.1 | 26/100⭐⭐ |
| Consumer Cyclical | +0.5% | -0.4% | -6.3% | 43.0 | 21/100⭐ |
| Technology | +0.6% | -2.3% | -9.6% | 40.7 | 17/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.